scholarly journals Therapeutic Strategies for Human Epidermal Receptor-2 Positive Metastatic Breast Cancer: A Literature Review

Cureus ◽  
2020 ◽  
Author(s):  
FNU Sapna ◽  
Pal Satyajit Singh Athwal ◽  
Mukesh Kumar ◽  
Sandeep Randhawa ◽  
Sukhmanii Kahlon
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Literature Review ◽  
Metastatic Breast ◽  
Therapeutic Strategies ◽  
Human Epidermal Receptor

Orbitotemporal Bone Cyst of Metastatic Breast Cancer: Case Report and Literature Review

2019 ◽  
Vol 130 ◽  
pp. 267-270
Author(s):  
Yoshifumi Tao ◽  
Kenji Yagi ◽  
Hirotake Nishimura ◽  
Keijirou Hara ◽  
Shunji Matsubara ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Case Report ◽  
Literature Review ◽  
Bone Cyst ◽  
Metastatic Breast ◽  
Breast Cancer Case ◽  
Cancer Case

The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer

2020 ◽  
Vol 26 (6) ◽  
pp. 1486-1491
Author(s):  
Jacopo Giuliani ◽  
Andrea Bonetti
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Dose Reduction ◽  
Endocrine Therapy ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Full Dose ◽  
Hormone Receptor Positive ◽  
Human Epidermal Receptor

The aim of this study was to assess the pharmacological costs of CDK4/6-inhibitors (palbociclib, ribociclib and abemaciclib) in hormone receptor positive (HR+)/human epidermal receptor 2-negative (HER2-) advanced or metastatic breast cancer (BC). We have considered pivotal phase III randomized controlled trials (RCTs) of palbociclib, ribociclib and abemaciclib for the treatment of postmenopausal women with HR+/HER2- advanced or metastatic BC in first-line in association with letrozole or anastrozole (scenario 1) and in subsequent-lines after progression or relapse during previous endocrine therapy (scenario 2).The costs of drugs are at the Pharmacy of our Hospital and are expressed in euros (€). Six phase III RCTs, including 3843 patients, were considered. In the scenario 1, abemaciclib resulted the less expensive at the full dose, with 2246 € per month of progression free survival (PFS)-gained. Overall ribociclib resulted the less expensive considering the reduction in dosage (36.1% in MONALEESA-2 trial versus (vs). 36.0% of palbociclib in PALOMA-2 trial vs. 43.4% of abemaciclib in MONARCH-3 trial). The price was the same for palbociclib and abemaciclib both at full and with dose reduction. In the scenario 2, the situation was similar to the scenario 1, but with lowest costs for ribociclib per month PFS-gained both at full dose (2070 €) and at dose reduction (1391 € and 690 € at 400 mg and 200 mg, respectively). Combining pharmacological costs of drugs with the measure of efficacy represented by the PFS, ribociclib was the less expensive in both scenarios.

scholarly journals Pseudocirrhosis: A Case Series and Literature Review

2016 ◽  
Vol 10 (2) ◽  
pp. 381-391 ◽  
Author(s):  
Abimbola Adike ◽  
Nina Karlin ◽  
Christine Menias ◽  
Elizabeth J. Carey
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Literature Review ◽  
Morphological Changes ◽  
Metastatic Cancer ◽  
Case Series ◽  
Metastatic Breast ◽  
Histopathological Changes ◽  
Hormone Receptor Positive ◽  
Important Complication

Pseudocirrhosis describes morphological changes of the liver that closely mimic cirrhosis, without the typical histopathological changes seen in cirrhosis. It most commonly occurs in patients with metastatic breast cancer, although it has been reported in other malignancies as well. Like in cirrhosis, portal hypertension is often seen in patients with pseudocirrhosis. Pseudocirrhosis is a rare but important complication of metastatic cancer. In this case series and literature review, we describe 6 patients with hormone-receptor-positive metastatic breast cancer. We report the significant morbidity associated with pseudocirrhosis in the course of treatment in patients with metastatic breast cancer.

Sign in / Sign up

Export Citation Format

Share Document